Susan Dana Jones, Ph.D., Vice President and Principal Consultant, is a seasoned biotechnology entrepreneur with experience in biopharmaceutical and vaccine product development, outsourcing, project management, and strategic planning. She co-founded two successful biotechnology companies and has managed multiple discovery and product development programs.
Dr. Jones is a subject matter expert in cell line development and characterization, cell culture, and process development for biosimilar, new biopharmaceutical, and vaccine development programs. She currently advises clients on the manufacturing requirements for advancement of product candidates from early discovery through all stages of clinical development. Dr. Jones also assists clients in applying appropriate cGMP regulations to their CMC programs and preparation of CMC regulatory submissions as well as performing technical due diligence for investors or companies seeking to in-license biopharmaceutical products.
Dr. Jones is a frequently invited speaker at industry conferences and symposia. She is a member of the Board of Directors of Gene Solutions, LLC, the Symphogen A/S Scientific Advisory Board, and the Editorial Advisory Board of BioProcess International.
Prior to joining BPTC, Dr. Jones was Senior Vice President of Corporate Development at Serenex, Inc, where she worked with other senior managers to complete a $15M Series B financing.
Prior to Serenex, she was Vice President of Product Development at Waratah Pharmaceuticals and previously held development and management positions of increasing responsibility at Peptimed Inc., Virus Research Institute (now Celldex Immunotherapeutics), IntraImmune Therapies Inc., and Dyax Corp.
Dr. Jones received her Bachelor’s degree in biochemistry from Harvard University, holds a Ph.D. in Genetics from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.